The startup develops RNA-only therapeutics that integrate genetic elements into safe harbor sites, enabling precise RNA-mediated insertion of transgenes. This approach addresses the need for targeted genetic medicine, offering patients a method for accurate and effective treatment options.

Adicet Bio develops allogeneic gamma delta CAR T cell therapies to target and eliminate cancer cells, utilizing the unique properties of gamma delta T cells for enhanced tissue homing and drug exposure. This approach addresses the need for effective, on-demand immunotherapies in the treatment of cancer and autoimmune diseases.

AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.

Anjarium Biosciences develops synthetic, enzymatically produced linear double-stranded DNA with customizable hairpin-ended structures to enhance the production of gene therapies. Their technology addresses the challenges of traditional plasmid DNA by providing faster production times, higher purity, and scalable solutions for various therapeutic applications.

Apellis Pharmaceuticals develops first‑in‑class C3‑targeted inhibitors to treat diseases caused by overactivation of the complement system. Its approved drug pegcetacoplan (SYFOVRE®/EMPAVELI®) blocks all three complement pathways and is used for geographic atrophy, paroxysmal nocturnal hemoglobinuria, and complement‑mediated kidney disorders, while its pipeline extends C3 inhibition to additional rare and renal diseases.

The startup develops multispecific antibodies that enhance the functionality of innate and adaptive immune cells, providing targeted engagement for improved therapeutic outcomes. This approach addresses the limitations of existing therapies by offering a more effective means to direct immune responses against diseases.

Entact Bio is developing enhancement-targeting chimeras (ENTACs) that utilize deubiquitylases to improve the function of critical proteins, addressing issues of protein deficiency, mislocation, and suboptimal activity in various diseases. Their Encompass™ platform enables the identification and optimization of these ENTACs to target previously undruggable pathways and treat complex genetic disorders.

Escient Pharmaceuticals develops first-in-class oral therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) to treat neurosensory-inflammatory disorders such as chronic urticaria and cholestatic pruritus. Their approach utilizes small molecule antagonists to address the underlying mechanisms of neurogenic inflammation, providing potential new treatment options for patients with limited existing therapies.

Gilead Sciences discovers, develops, and delivers innovative therapeutics for serious viral, oncologic, and inflammatory diseases, maintaining a portfolio of over 25 approved medicines and a pipeline of 47 clinical‑stage programs. The company expands global access through licensing, partnerships, and philanthropy, reaching patients in more than 120 countries while integrating ESG initiatives to support sustainable health outcomes.

Glycomine is developing GLM101, a mannose-1-phosphate replacement therapy currently in clinical trials for PMM2-CDG, a rare genetic disease caused by glycosylation defects. This therapy aims to restore the missing biochemical function, offering potential disease modification rather than merely symptomatic relief.

HilleVax is developing novel vaccines targeting norovirus, which is responsible for over 90% of epidemic non-bacterial gastroenteritis outbreaks and leads to approximately 200,000 deaths annually. The company's focus on vaccine commercialization aims to mitigate the significant global economic burden of norovirus, estimated at $60.3 billion each year.

Jasper Therapeutics develops briquilimab, a targeted anti c-Kit monoclonal antibody that depletes mast cells and diseased stem cells to enhance the safety and efficacy of hematopoietic stem cell transplants. The company focuses on treating chronic conditions such as asthma and chronic urticaria, as well as rare genetic disorders like sickle cell disease and severe combined immunodeficiency.

Nido provides an AI-assisted platform for HVAC and renewables professionals to streamline project execution from quoting to installation. The software generates instant 3D plans, electrical/hydraulic diagrams, and branded professional offers, significantly reducing proposal creation time. It also manages project tracking, purchasing, and automates compliance documentation for certifications and subsidies.

The startup has developed an immunotherapy platform that utilizes engineered viral vectors to express tumor neoantigens, facilitating robust antitumor T-cell responses. This technology aims to enhance cancer-specific cellular immunity, addressing the need for more effective cancer treatments.

NuCana develops phosphoramidate (ProTide) prodrugs that convert nucleoside analogs into monophosphate forms, enabling transporter‑independent cellular uptake and resistance to enzymatic degradation. This platform delivers higher intracellular concentrations of active metabolites, reducing toxic by‑products and improving safety in solid‑tumor chemotherapy, exemplified by NUC‑7738 and NUC‑3373, which are being evaluated as monotherapy and in combination with PD‑1 inhibitors.

OnKure Therapeutics discovers and develops tumor‑agnostic small‑molecule therapies that target shared oncogenic driver mutations across cancer types. It leverages pan‑cancer genomic mining, structure‑based drug design, and preclinical models (PDX, organoids) to validate compounds and co‑develop companion diagnostics, enabling biomarker‑driven adaptive trials for oncology clinicians and pharmaceutical partners.

Opthea develops OPT‑302, a biologic that selectively binds VEGF‑C and VEGF‑D to block VEGFR‑3 activation. By targeting this pathway, the therapy aims to reduce retinal vascular leakage in wet age‑related macular degeneration and curb pathological lymphatic remodeling in patients with lymphangioleiomyomatosis, complementing existing anti‑VEGF‑A treatments.

Pathalys Pharma develops upacicalcet, a novel intravenous calcimimetic designed to treat secondary hyperparathyroidism in patients with late-stage chronic kidney disease. This therapeutic addresses the critical issue of elevated parathyroid hormone levels resulting from kidney failure, which can lead to severe complications in affected patients.

Q32 Bio develops targeted biotherapeutics that re-regulate immune function to treat severe autoimmune and inflammatory diseases. Their lead candidates, Bempikibart and ADX-097, are designed to modulate adaptive and innate immune responses, respectively, addressing conditions such as atopic dermatitis and ANCA-Associated Vasculitis.

Solve Therapeutics develops Antibody Drug Conjugates and Bispecific Therapeutics to target and eliminate cancer cells while minimizing damage to healthy tissue. Their approach addresses the need for more effective and less toxic cancer treatment options in the biopharmaceutical landscape.

Artemis is an ultra‑low‑power ASIC accelerator that operates at near‑threshold voltage (≈0.275 V) and uses an asynchronous massively parallel architecture to deliver AI inference with about 35 % lower power consumption than comparable HPC accelerators. The platform integrates on‑chip ADCs, vector extensions, and a CXL‑compatible interconnect to enable near‑data processing and coherent memory access for hyperscale data‑center and edge AI workloads.

Spruce Biosciences develops Tralesinidase Alfa (TA-ERT), an enzyme replacement therapy that restores deficient N‑acetyl‑α‑glucosaminidase activity in the brain of patients with Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). Using a proprietary delivery platform to cross the blood‑brain barrier, the therapy targets glycosaminoglycan accumulation to halt or reverse neurodegeneration, and is progressing toward a Biologics License Application in late 2026.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune diseases. The company's lead program, CM313, is an IgG1 monoclonal antibody targeting CD38 to modulate immune cell activity. This asset is being advanced across multiple indications, including Immune Thrombocytopenia and Systemic Lupus Erythematosus, addressing significant unmet medical needs.

Venatorx Pharmaceuticals develops novel anti-infectives targeting multi-drug-resistant bacterial and challenging viral infections through advanced drug discovery and development techniques. The company addresses the urgent need for effective treatments in the face of rising antibiotic resistance and limited therapeutic options.